ABSTRACT:
Due to their characteristics of biocompatibility, biodegradability, and extended circulating half-life, erythrocytes, also known as red blood cells or RBCs, are the most prevalent circulating cells in the blood and have found extensive application in drug delivery systems (DDS). In light of this, an erythrocyte-based "camouflage" membranes creates a platform for nanoparticles that combines the benefits of native erythrocyte membranes with nanomaterial-based ones. When administered intraperitoneally to animal models, the coated In order to accomplish long-term circulation, nanoparticles mimic RBCs and interact with their surroundings. The erythrocyte membrane-coated nano-cores biomimetic platform is reviewed in this paper with an emphasis on the coating mechanism, preparation techniques, and verification. techniques, as well as the newest anti-tumor software. Lastly, further erythrocyte functional alterations membranes and efforts to combine the characteristics of several cell membranes on their surface are examined. establishing a framework to encourage in-depth study of multifunctional nano-biomimetic systems
Cite this article:
Nikita Vilas Patel, Amitkumar R. Dhankani, S.P. Pawar. A Review of Red Blood Cell Membrane Camouflaged Nanoparticles (Anti-Tumor). Asian Journal of Pharmacy and Technology. 2026; 16(2):201-6. doi: 10.52711/2231-5713.2026.00029
Cite(Electronic):
Nikita Vilas Patel, Amitkumar R. Dhankani, S.P. Pawar. A Review of Red Blood Cell Membrane Camouflaged Nanoparticles (Anti-Tumor). Asian Journal of Pharmacy and Technology. 2026; 16(2):201-6. doi: 10.52711/2231-5713.2026.00029 Available on: https://ajptonline.com/AbstractView.aspx?PID=2026-16-2-14
REFERENCES:
1. Kang L, Gao Z, Huang W, Jin M, Wang Q. Nanocarrier-mediated co-delivery of chemotherapeutic drugs and gene agents for cancer treatment. Acta Pharm Sin B. 2015; 5: 169–75.
2. Weng Y, Liu J, Jin S, Guo W, Liang X, Hu Z. Nanotechnology-based strategies for treatment of ocular disease. Acta Pharm Sin B. 2017; 7:281–91.
3. Fang J, Qin H, Nakamura H, Tsukigawa K, Shin T, Maeda H. Carbon monoxide, generated by heme oxygenase-1, mediates the enhanced permeability and retention effect in solid tumors. Cancer Sci. 2012; 103:535–41.
4. Iwamoto T. Clinical application of drug delivery systems in cancer chemotherapy: review of the efficacy and side effects of approved drugs. Biol Pharm Bull. 2013; 36:715–8.
5. Chen MC, Lin ZW, Ling MH. Near-infrared light-activatable microneedle system for treating superficial tumors by combination of chemotherapy and photothermal therapy. ACS Nano. 2016; 10:93–101.
6. Ihler GM, Glew RH, Schnure FW. Enzyme loading of erythrocytes. Proc Natl Acad Sci USA. 1973; 70:2663–6.
7. Pierigè F, Serafini S, Rossi L, Magnani M. Cell-based drug delivery. Adv Drug Deliv Rev. 2008; 60: 286–95.
8. Hamidi M, Tajerzadeh H. Carrier erythrocytes: an overview. Drug Deliv. 2003; 10: 9–20.
9. Patel PD, Dand N, Hirlekar RS, Kadam VJ. Drug loaded erythrocytes: as novel drug delivery system. Curr Pharm Des. 2008; 14: 63–70.
10. Dehaini D, Wei X, Fang RH, Masson S, Angsantikul P, Luk BT, et al. Erythrocyte-platelet hybrid membrane coating for enhanced nanoparticle functionalization. Adv Mater. 2017; 29: 1606209.
11. Yoo JW, Irvine DJ, Discher DE, Mitragotri S. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Discov. 2011; 10: 521–35.
12. Wang C, Sun X, Cheng L, Yin S, Yang G, Li Y, et al. Multifunctional theranostic red blood cells for magnetic-field-enhanced in vivo combination therapy of cancer. Adv Mater. 2014; 26: 4794–802.
13. Sun X, Wang C, Gao M, Hu A, Liu Z. Remotely controlled red blood cell carriers for cancer targeting and near-infrared lighttriggered drug release in combined photothermal-chemotherapy. Adv Funct Mater. 2016; 12: 548
14. Doshi N, Zahr AS, Bhaskar S, Lahann J, Mitragotri S. Red blood cell-mimicking synthetic biomaterial particles. Proc Natl Acad Sci USA. 2009; 106: 21495–9.
15. Tsai RK, Rodriguez PL, Discher DE. Self inhibition of phagocytosis: the affinity of 'marker of self' CD47 for SIRP alpha dictates potency of inhibition but only at low expression levels. Blood Cells Mol Dis. 2010; 45: 67–74.
16. Merkel TJ, Jones SW, Herlihy KP, Kersey FR, Shields AR, Napier M, et al. Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles. Proc Natl Acad Sci USA. 2011; 108:586–91.
17. Marsden NV, Ostling SG. Accumulation of dextran in human red cells after haemolysis. Nature. 1959; 184(Suppl 10): 723–4.
18. Jain S, Jain NK. Engineered erythrocytes as a drug delivery system. Indian J Pharm Sci. 1997; 59: 275–81.
19. Hu CM, Fang RH, Zhang L. Erythrocyte-inspired delivery systems. Adv Healthc Mater. 2012; 1: 537–47.
20. Lejeune A, Moorjani M, Gicquaud C, Lacroix J, Poyet P, Gaudreault R. Nanoerythrosome, a new derivative of erythrocyte ghost: preparation and antineoplastic potential as drug carrier for daunorubicin. Anticancer Res. 1994; 14: 915–9.
21. Desilets J, Lejeune A, Mercer J, Gicquaud C. Nanoerythrosomes, a new derivative of erythrocyte ghost: iv. Fate of reinjected nanoerythrosomes. Anticancer Res 2001; 21:1741–7.
22. Hu CM, Fang RH, Copp J, Luk BT, Zhang L. A biomimetic nanosponge that absorbs pore-forming toxins. Nat Nanotechnol. 2013; 8: 336–40.
23. Ihler GM, Tsang HC. Hypotonic hemolysis methods for entrapment of agents in resealed erythrocytes. Methods Enzymol. 1987; 149:221–9.
24. Sato Y, Yamakose H, Suzuki Y. Mechanism of hypotonic hemolysis of human erythrocytes. Biol Pharm Bull. 1993; 16:506–12.
25. Seth M, Ramachandran A, Leal LG. Dilution technique to determine the hydrodynamic volume fraction of a vesicle suspension. Langmuir. 2010; 26: 15169–76.
26. Bird J, Best R, Lewis DA. The encapsulation of insulin in erythrocytes. J Pharm Pharmacol. 1983; 35:246–7.
27. Gutierrez MC, Zarzuelo CA, Sayalero MM, Lanao JM. Factors associated with the performance of carrier erythrocytes obtained by hypotonic dialysis. Blood Cells Mol Dis. 2004; 33: 132–40
28. Tajerzadeh H, Hamidi M. Evaluation of hypotonic preswelling method for encapsulation of enalaprilat in intact human erythrocytes. Drug Dev Ind Pharm. 2000; 26: 1247–57.
29. Hamidi M, Zarrin AH, Foroozesh M, Zarei N, Mohammadi-Samani S. Preparation and in vitro evaluation of carrier erythrocytes for REStargeted delivery of interferon-α2b. Int J Pharm. 2007; 341: 125–33.
30. Franco RS, Barker R, Novick S, Weiner M, Martelo OJ. Effect of inositol hexaphosphate on the transient behavior of red cells following a DMSO-induced osmotic pulse. J Cell Physiol. 1986; 129: 221–9.
31. Watts TJ, Handy RD. The haemolytic effect of verapamil on erythrocytes exposed to varying osmolarity. Toxicol Vitr. 2007; 21: 835–9.
32. Lynch AL, Chen R, Slater NK. pH-responsive polymers for trehalose loading and desiccation protection of human red blood cells. Biomaterials. 2011; 32: 4443–9.
33. Choi SO, Kim YC, Park JH, Hutcheson J, Gill HS, Yoon YK, et al. An electrically active microneedle array for electroporation. Biomed Microdevices. 2010; 12: 263–73.
34. Ren X, Zheng R, Fang X, Wang X, Zhang X, Yang W, et al. red blood cell membrane camouflaged magnetic nanoclusters for imaging-guided photothermal therapy. Biomaterials. 2016; 92: 13–24.
35. Zhai Y, Su J, Ran W, Zhang P, Yin Q, Zhang Z, et al. Preparation and application of cell membrane-camouflaged nanoparticles for cancer therapy. Theranostics. 2017; 7:2575–92.
36. Hu CM, Fang RH, Wang KC, Luk BT, Thamphiwatana S, Dehaini D, et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature. 2015; 526: 118–21.
37. Su J, Sun H, Meng Q, Yin Q, Tang S, Zhang P, et al. long circulation red-blood-cell mimetic nanoparticles with peptide-enhanced tumor penetration for simultaneously inhibiting growth and lung metastasis of breast cancer. Adv Funct Mater. 2016; 26: 1243– 52.
38. Fang RH, Hu CM, Zhang L. Nanoparticles disguised as red blood cells to evade theimmune system. Expert Opin Biol Ther. 2012; 12: 385–9.
39. Schauer R. Sialic acids as regulators of molecular and cellular interactions. Curr Opin Struct Biol. 2009; 19: 507–14.
40. Kelm S, Schauer R. Sialic acids in molecular and cellular interactions. Int Rev Cytol. 1997; 175: 137–240.
41. Raveendran P, Fu J, Wallen SL. Completely “green” synthesis and stabilization of metal nanoparticles. J Am Chem Soc. 2003; 125: 13940–1.
42. Lemarchand C, Gref R, Couvreur P. Polysaccharide-decorated nanoparticles. Eur J Pharm Biopharm. 2004; 58: 327–41.
43. Luk BT, Hu CM, Fang RH, Dehaini D, Carpenter C, Gao W, et al. Interfacial interactions between natural RBC membranes and synthetic polymeric nanoparticles. Nanoscale. 2014; 6: 2730–7.
44. Hu CM, Fang RH, Luk BT, Chen KN, Carpenter C, Gao W, et al. ‘Marker-of-self’ functionalization of nanoscale particles through a topdown cellular membrane coating approach. Nanoscale. 2013; 5: 2664–8.
45. Hu CM, Zhang L, Aryal S, Cheung C, Fang RH, Zhang L. Erythrocyte membrane camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci USA. 2011; 108: 10980–5.
46. Rao L, Cai B, Bu LL, Liao QQ, Guo SS, Zhao XZ, et al. Microfluidic electroporation facilitated synthesis of erythrocyte membrane-coated magnetic nanoparticles for enhanced imaging guided cancer therapy. ACS Nano. 2017; 11: 3496–505.
47. Miyazaki J, Aihara H. Gene transfer into muscle by electroporation in vivo. Methods Mol Med. 2002; 69: 49–62.
48. Wang X, Li H, Liu X, Tian Y, Guo H, Jiang T, et al. Enhanced photothermal therapy of biomimetic polypyrrole nanoparticles through improving blood flow perfusion. Biomaterials. 2017; 143: 130–41.